English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the last few years, the emergence of new high throughput molecular technologies allowed a never-before-seen insight into the genetic, epigenetic, transcriptomic and proteomic background of cancers. These studies have been performed in a large number of patients’ samples and provided a great amount of data. Current efforts to translate these new findings into therapeutic strategies are ongoing, but already provided significant information which may change clinical practice in the near future. As a result of this development, the most frequent molecular alterations and affected pathways responsible for the formation and progression of prostate cancer have been identified. In this review, we provide an overview on the current progress in primary and metastatic prostate cancer research focusing on the molecular subtype classification and the most frequently dysregulated pathways, such as androgen signaling, PI3K pathway, cell cycle and DNA repair regulation. In this context, we highlight therapies already approved or are currently under clinical investigation for prostate cancer. Orv Hetil. 2019; 160(7): 252–263.

A prosztatarák molekuláris altípusai és célzott terápiás kilátásai